2024
Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftment
2022
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients
Olsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeSmall fiber neuropathyAdverse eventsPlasma exchangeLower extremity paresthesiasSymptomatic response rateAutoantibody-mediated disorderSkin biopsy resultsSFN symptomsTS-HDSExtremity paresthesiasPeripheral neuropathySymptomatic improvementCase seriesIgM antibodiesMean ageTPE proceduresBiopsy resultsTreatment optionsDisease progressionIgM classVasovagal reactionsClose monitoringLaboratory confirmationResponse rateEarly but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patientsThe use of 4F‐PCC to correct direct oral anticoagulant‐induced coagulopathy: An observational analysis
Zheng Y, Tormey CA. The use of 4F‐PCC to correct direct oral anticoagulant‐induced coagulopathy: An observational analysis. Transfusion Medicine 2020, 30: 304-307. PMID: 32342588, DOI: 10.1111/tme.12683.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsThromboembolic eventsFour-factor prothrombin complex concentrateLevel 1 trauma centerAdditional prospective studiesRetrospective observational studyProthrombin complex concentrateOff-label useEmergent surgeryOral anticoagulantsMost patientsClinical outcomesTrauma centerHgb levelsProspective studyLabel indicationsComplex concentrateSevere hemorrhageObservational studyHemorrhage sizePatientsCoagulopathyAdministrationBleedingHemorrhagePassive anti‐C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series
Sostin N, Ross R, Balbuena‐Merle R, Hendrickson JE, Tormey CA. Passive anti‐C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series. Journal Of Clinical Apheresis 2020, 35: 224-226. PMID: 32110829, DOI: 10.1002/jca.21773.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsRh immune globulin administrationRisk/benefit ratioApheresis platelet transfusionImmune globulin administrationRhIG immunoprophylaxisImmune globulinTransfusion supportAlloantibody formationCase seriesNegative recipientsAlloimmunization riskRhIG administrationReproductive agePassive transferPLT transfusionsTransfusionBlood bankBenefit ratioRhIGApheresis PLTsAdministrationImmunoprophylaxisPatientsSetting
2019
Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionResponders
2018
False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restrictionMorphology and flow cytometry of atypical basophils
Tormey CA, Siddon AJ. Morphology and flow cytometry of atypical basophils. Blood 2018, 132: 552. PMID: 30072417, DOI: 10.1182/blood-2018-05-850073.Peer-Reviewed Original ResearchRisk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Hendrickson JE, Study‐III N. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database. British Journal Of Haematology 2018, 181: 672-681. PMID: 29675950, PMCID: PMC5991618, DOI: 10.1111/bjh.15182.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnemia, Sickle CellArthritis, RheumatoidBlood DonorsBlood Group AntigensChildChild, PreschoolDatabases, FactualErythrocyte TransfusionFemaleHumansImmunizationInfantIsoantibodiesLupus Erythematosus, SystemicMaleMiddle AgedMyelodysplastic SyndromesRisk FactorsTransfusion ReactionConceptsRed blood cell alloimmunizationRecipient EpidemiologyRecipients databaseSignificant RBC alloantibodiesNegative antibody screenLargest RBCStandardized registryPositive patientsRBC alloantibodiesAntibody screenICD9/10 codesPatient cohortRisk factorsResponder statusCertain diagnosisBlood typeLarger studyAlloimmunizationRhD statusStudy databaseRespondersPatientsDisease associationsPotential correlatesEpidemiology
2017
A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization
Celli R, Schulz W, Hendrickson JE, Tormey CA. A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sanguinis 2017, 112: 469-472. PMID: 28337751, DOI: 10.1111/vox.12515.Peer-Reviewed Original ResearchIrradiation of Red Blood Cells and Alloimmunization
Tormey CA, Hendrickson JE. Irradiation of Red Blood Cells and Alloimmunization. Lab Medicine 2017, 48: 172-177. PMID: 28340248, DOI: 10.1093/labmed/lmx018.Peer-Reviewed Original ResearchConceptsAlloimmunization rateRBC alloimmunization rateTime of transfusionRBC unit transfusionPostoperative bleedingRed blood cell damageRed blood cellsRBC transfusionCommon diagnosisImmunosuppressive disordersTransfusion recipientsBlood cell damageAnimal modelsStudy subjectsTransfusionControl groupRBC antigensAntibody screeningRBC unitsPatientsBlood cellsCell damageRBCsOxidative damageDiagnosis
2015
Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Siddon AJ, Rinder HM, Hendrickson JE, Tormey CA. Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage? Annals Of Hematology 2015, 94: 1413-1414. PMID: 26027859, DOI: 10.1007/s00277-015-2406-z.Peer-Reviewed Original Research
2014
The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital
Gehrie EA, Tormey CA. The Development and Implementation of, and First Years' Experience With, a Massive/Emergency Transfusion Protocol (Damage Control Hematology Protocol) in a Veterans Affairs Hospital. Military Medicine 2014, 179: 1099-1105. PMID: 25269127, DOI: 10.7205/milmed-d-14-00045.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood BanksBlood Grouping and CrossmatchingBlood Loss, SurgicalBlood TransfusionClinical AuditClinical ProtocolsConnecticutEmergenciesErythrocyte TransfusionFactor VIIaFactor VIIIFibrinogenHematemesisHospitals, VeteransHumansLaboratories, HospitalMalePlasma ExchangePlatelet TransfusionPostoperative HemorrhageRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsConceptsFresh frozen plasmaRecombinant factor VIIaRed blood cellsVeterans Affairs hospitalTransfusion protocolFactor VIIaUnits of RBCsVeterans Affairs Connecticut Healthcare SystemUnits of FFPLarge trauma centersHospital-based blood banksETP patientsMassive transfusionTrauma centerFrozen plasmaSeparate patientsPatientsWest HavenBleeding emergenciesBlood bankBlood cellsYears' experienceHealthcare systemPlateletsHospital
2013
Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients
Winkler AM, Tormey CA. Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal Of Clinical Pathology 2013, 140: 610-622. PMID: 24124139, DOI: 10.1309/ajcp9vjs6kuknchw.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorAvailable direct thrombin inhibitorThrombin inhibitorsDegree of anticoagulationLife-threatening bleedsExperimental animal modelsSupportive careBleeding patientsCase reportClinical trialsFactor concentratesRoutine coagulationAnticoagulant effectPharmacologic propertiesAnimal modelsThrombin timeTransfusion productsPathology consultationAnticoagulationDrug concentrationsLaboratory assessmentNewer assaysDrug removalBleedingPrimary authorAllergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components
Xiao W, Tormey CA, Capetillo A, Maitta RW. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sanguinis 2013, 105: 334-340. PMID: 23802769, DOI: 10.1111/vox.12063.Peer-Reviewed Original ResearchConceptsAllergic transfusion reactionsTransfusion reactionsATR rateApheresis plateletsPlatelet componentsApheresis componentsAcademic medical centerABO mismatchAdverse eventsAntigen exposurePlatelet transfusionsPlatelet countDonor factorsMedical CenterApheresis productsApheresis unitsPlatelet productsStudy periodTransfusionPlateletsSimilar ratesFurther investigationLimiting the Extent of a Delayed Hemolytic Transfusion Reaction With Automated Red Blood Cell Exchange
Tormey CA, Stack G. Limiting the Extent of a Delayed Hemolytic Transfusion Reaction With Automated Red Blood Cell Exchange. Archives Of Pathology & Laboratory Medicine 2013, 137: 861-4. PMID: 23721278, DOI: 10.5858/arpa.2012-0154-cr.Peer-Reviewed Original ResearchConceptsRed blood cell exchangeHemolytic transfusion reactionsDAT resultsTransfusion reactionsDirect antiglobulin test resultsCell exchangeIncompatible red blood cellsSymptoms of hemolysisRed blood cell unitsPositive antibody screenBlood group antibodiesAntigen-negative unitsAnamnestic increaseAntigen reexposureFurther hemolysisRed blood cellsAntibody screenGroup antibodiesPatient historyBlood cellsDHTRTransfusionHemolysisSymptomsCell unitsThe Development of a Novel Molecular Assay Examining the Role of Aminopeptidase P Polymorphisms in Acute Hypotensive Transfusion Reactions
Hui Y, Wu Y, Tormey CA. The Development of a Novel Molecular Assay Examining the Role of Aminopeptidase P Polymorphisms in Acute Hypotensive Transfusion Reactions. Archives Of Pathology & Laboratory Medicine 2013, 137: 96-9. PMID: 23276181, DOI: 10.5858/arpa.2011-0466-oa.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAgedAminopeptidasesAngiotensin-Converting Enzyme InhibitorsBase SequenceBradykininCase-Control StudiesDNA PrimersFemaleGenetic Predisposition to DiseaseHeterozygoteHomozygoteHumansHypotensionMaleMiddle AgedPolymerase Chain ReactionPolymorphism, Single NucleotideTransfusion ReactionConceptsAcute hypotensive transfusion reactionsHypotensive transfusion reactionsACE-IsTransfusion reactionsSingle nucleotide polymorphismsMolecular assaysHarmful adverse effectsPolymerase chain reactionBradykinin degradationPatientsEnzyme inhibitorsBradykinin generationAPP geneNovel molecular assayPilot studyAdverse effectsChain reactionFurther studiesAminopeptidase PXPNPEP2PolymorphismAssaysAPP activitySequencing resultsTransfusion